1. Arango V, Underwood MD, Mann JJ. Alterations in monoamine receptors in the brain of suicide victims. J Clin Psychopharmacology 1992;12:8–12.

2. Arora RC, Meltzer HY. Increased serotonin 2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sci 1989;44:725–734.

3. Blier P, de Montigny G, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51:14–20.

4. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr. The antidepressants fluoxetine, idazaxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992;572:117–125.

5. Calogero AE, Bagdy G, Moncada ML, D'Agata R. Effect of selective serotinin agonists on basal, corticotropin-releasing hormone-induced and vasopressin-induced ACTH release in vitro from rat pituitary cells. J Endocrinology 1993;136:381–387.

6. Carlsson M, Svensson K, Ericksson E, Carlsson A. Rat brain serotonin: biochemical and functional evidence for a sex difference. J Neural Transm 1985;63:297–313.

7. Celada P, Dolera M, Alvarez E, Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationships to clinical improvement. J Affect Disord 1992;25:243–250.

8. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Rev 1993; 18:1–32.

9. Charney DS, Delgado PL. Current concepts of the role of serotonin function in depression and anxiety. In: Langer SZ, Brunello N, Racagni G, Mendlewicz J, eds. Serotonin receptor subtypes: pharmacological significance and clinical implication. Basel: Karger, 1992;89–104.

10. Cheetham SC, Crompton MR, Czudek C, Horton RW, Katona CL, Reynolds GP. Serotonin concentrations and turnover in brains of depressed suicides. Brain Res 1989;502:332–340.

11. Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 1988;443:272–280.

12. Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology 1990;102:544–548.

13. Cowen PJ. A role for 5-HT in the action of antidepressant drugs. Pharmacol Ther 1990;46:43–51.

14. Curzon G. 5-Hydroxytryptamine and corticosterone in an animal model of depression. Prog Psychopharmacol Biol Psychiatry 1989; 13:305–310.

15. Deakin JF, Pennell I, Upadhyaya AJ, Lofthouse R. A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology 1990;101:85–92.

16. Delgado PL, Charney DS, Price LH, Landis H, Heninger GR. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci 1990;45:2323–2332.

17. Faustman WO, King RJ, Faull KF, Moses JA Jr, Benson KL, Zarcone VP, Csernansky JG. MMPI measures of impulsivity and depression correlate with CSF 5-HIAA and HVA in depression but not schizophrenia. J Affect Disord 1991;22:235–239.

18. Fuller RW. The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 1992;13:250–270.

19. Golden RN, Ekstrom D, Brown TM, Ruegg R, Evans DL, Haggerty JJ Jr, Garbutt JC, Pedersen CA, Mason GA, Browne J. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 1992;149:1168–1175.

20. Gross-Isseroff R, Israeli M, Biegon A. Autoradiographic analysis of initiated imipramine binding in the human brain post-mortem: effects of suicide. Arch Gen Psychiatry 1989;46:237–241.

21. Haleem DJ, Kennett GA, Whitton PS, Curzon G. 8-OH-DPAT increases corticosterone but not other 5-HT1A receptor-dependent responses more in females. Eur J Pharmacol 1989;164:435–443.

22. Hayakawa H, Yokota N, Shimizu M, Nishida A, Yamawaki S. Repeated treatment with electroconvulsive shock increases numbers of serotonin-1A receptors in the rat hippocampus. Biog Amine 1993;4:295–306.

23. Heninger GR, Delgado PL, Charney DS, Price LH, Aghajanian GK. Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients. J Chem Neuroanatomy 1992;5:347–348.

24. Hensler JG, Kovachich GB, Frazer A. A quantitative autoradiographic study of serotonin 1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropharmacology 1991;25:563–576.

25. Hoes MJAJM, Sijben N. The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. Psychopharmacology 1981;75:346–349.

26. Huether G, Hajak G, Reimer A, Poeggeler B, Blomer M, Rodenbeck A, Ruther E. The metabolic fate of infused L-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites. Psychopharmacology 1992;109:422–432.

27. Jhamandas K, Boegman RJ, Beninger RJ, Bialik M. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res 1990;529:185–191.

28. Koyama T, Meltzer HY. A biochemical and neuroendocrine study of the serotonergic system in depression. In: Hippius H., ed. New results in depression research, Berlin-Heidelberg: Springer-Verlag; 1986:169–188.

29. Kuroda Y, Mikuni M, Ogawa T, Takahashi K. Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors. Psychopharmacology 1992;108:27–32.

30. Lawrence KM, DePaermentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain 5-HT uptake sites, labelled with [3H]paroxetine, in antidepressant-free depressed suicides. Brain Res 1990;526:17–22.

31. Lawrence KM, Falkowski J, Jacobson RR, Horton RW. Platelet 5-HT uptake sites in depression—3 concurrent measures using 3H-imipramine and 3H-paroxetine. Psychopharmacology 1993;110: 235–239.

32. Leake A, Fairbairn AF, McKeith IG, Ferrier IN. Studies on the serotonin uptake binding site in major depressive disorder and control port-mortem brain: neurochemical and clinical correlates. Psychiatr Res 1991;39:155–165.

33. Lerer B. Neurochemical and other neurobiological consequences of ECT: implications for the pathogenesis and treatment of affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:577–588.

34. Lesch K-P, Mayer S, Disselkamp-Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM. 5-HT1A receptor responsivity in unipolar depression: evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990;28:620–628.

35. Leysen JE. 5-HT2 receptors: location, pharmacological, pathological and physiological role: In: Langer SZ, Brunello N, Racagni G, Mendlewicz J, eds. Serotonin receptor subtypes: pharmacological significance and clinical implication. Basel: Karger, 1992:31–43.

36. Lichtenberg P, Shapira B, Gillon D, Kindler S, Cooper TB, Newman ME, Lerer B. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatr Res 1992;43:137– 146.

37. Lund A, Mjellem-Jolly N, Hole K. Desipramine, administered chronically, influences 5-hydroxytryptamine 1A-receptors, as measured by behavioral tests and receptor binding in rats. Neuropharmacology 1992;31:25–32.

38. Maes M, De Ruyter M, Claes R, Bosma G, Suy E. The cortisol responses to 5-hydroxytryptophan, orally, in depressive inpatients. J Affect Disord 1987;13:23–30.

39. Maes M, De Ruyter M, Suy E. The renal excretion of xanthurenic acid following L-tryptophan loading in depressed patients. Human Psychopharmacology 1987;2:231–235.

40. Maes M, D'Hondt P, Martin M, Claes M, Schotte C, Vandewoude M, Blockx P. L-5-hydroxytryptophan stimulated cortisol escape from dexamethasone suppression in melancholic patients. Acta Psychiatr Scand 1991;83:302–306.

41. Maes M, D'Hondt P, Suy E, Minner B, Vandervorst C, Raus J. HPA-axis hormones and prolactin responses to dextro-fenfluramine in depressed patients and healthy controls. Prog Neuro-Psychopharmacol Biol Psychiatry 1991;15:781–790.

42. Maes M, Jacobs M-P, Suy E, Minner B, Leclercq C, Christiaens F, Raus J. Suppressant effects of dexamethasone on the availability of plasma L-tryptophan and tyrosine in healthy controls and in depressed patients. Acta Psychiatr Scand 1990;81:19–23.

43. Maes M, Maes L, Schotte C, Vandewoude M, Martin M, D'Hondt P, Blockx P, Scharpé S, Cosyns P. Clinical subtypes of unipolar depression, part III: Quantitative differences in various biological markers between the cluster analysis-generated non-vital and vital depression classes. Psychiatr Res 1990;34:59–75.

44. Maes M, Minner B, Suy E. The relationships between the availability of L-tryptophan to the brain, the spontaneous HPA-axis activity, and the HPA-axis responses to dexamethasone in depressed patients. Amino Acids 1991;1:57–65.

45. Maes M, Vandervorst C, Suy E, Minner B, Raus J. A multivariate study on the simultaneous urinary free cortisol, plasma cortisol, adrenocorticotropic hormone and b-endorphin escape from suppression by dexamethasone in melancholic patients. Acta Psychiatr Scand 1991;83:480–491.

46. Maes M, Vandevelde R, Suy E. Influences on cortisol and noradrenergic turnover of healthy controls and depressed patients during L-tryptophan loading. J Affect Disord 1989;17:173–182.

47. Maj J, Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm 1992;88:143–156.

48. Matsubara S, Arora RC, Meltzer HY. Serotonergic measures in suicide brain: 5-HT1A binding sites in frontal cortex of suicide victims. J Neural Transm 1991;85:181–194.

49. Mellerup ET, Plenge P, Engelstoft M. High affinity binding of 3H-paroxetine and 3H-imipramine to human platelet membranes. Eur J Pharmacology 1983;96:303–309.

50. Meltzer HY, Arora RC. Platelet serotonin studies in affective disorders: evidence for a serotonergic abnormality. In: Sandler M, Coppen A, Harnett S, eds. 5-Hydroxytryptamine in psychiatry: a spectrum of ideas. New York: Oxford University Press, 1991:50–89.

51. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:513–526.

52. Meltzer HY, Maes M. Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology 1993;[in press].

53. Meltzer HY, Maes M. Effects of buspirone on cortisol and prolactin secretion in major depression. Biol Psychiatry 1994;35:316–323.

54. Meltzer HY, Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders: enhanced response in depression and mania. Arch Gen Psychiatry 1984;41:366–374.

55. Mikuni M, Kagaya A, Takahashi K, Meltzer HY. Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders. Psychopharmacology 1992;106:311–314.

56. Møller SE, Bech P, Bjerrum H, Bøjholm S, Butler B, Folker H, Gram LF, Larsen JK, Lauritzen L, Loldrup D, Munk-Andersen E, Odum K, Rafaelson OJ. Plasma ratio tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. J Affect Disord 1990;18:59–66.

57. Morgan CJ, Badawy AA-B. Effects of a suppression test dose of dexamethasone on tryptophan metabolism and disposition in the rat. Biol Psychiatry 1989;25:360–362.

58. Nash JF, Meltzer HY. Neuroendocrine studies in psychiatric disorders: the role of serotonin. In: Brown S-L, van Praag HM, eds. The role of serotonin in psychiatric disorders. New York: Brunner/Mazel, 1991:57–90.

59. Nuller JL, Ostroumova MN. Resistance to inhibiting effect of dexamethasone in patients with endogenous depression. Acta Psychiatr Scand 1980;61:169–177.

60. O'Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991;148:1009–1015.

61. O'Keane V, McLoughlin D, Dinan TG. D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. J Affect Disord 1992;26:143–150.

62. Pranzatelli MR, Eng B. Chronic ACTH treatment: influence on 5-HT2 receptors and behavioral supersensitivity induced by 5,7-dihydroxytryptamine lesions. Peptides 1989;10:5–8.

63. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS. CSF amine metabolites in depression. Biol Psychiatry 1992; 31:112–118.

64. Sarrias MJ, Artigas F, Martinez E, Gelpi E, Alvarez E, Udina C, Casas M. Decreased plasma serotonin in melanchoic patients: a study with clomipramine. Biol Psychiatry 1987;22:1429–1438.

65. Seckl JR, Fink G. Use of in situ hybridization to investigate the regulation of hippocampal corticosteroid receptors by monoamines. J Steroid Biochem Mol Biol 1991;40:685–688.

66. Shapira B, Cohen J, Newman ME, Lerer B. Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biol Psychiatry 1992;33:531–535.

67. Sharpley AL, Gregory CA, Solomon RA, Cowen PJ. Slow wave sleep and 5-HT2 receptor sensitivity during maintenance tricyclic antidepressant treatment. J Affect Disord 1990;19:273–277.

68. Singh VB, Hao-Phan T, Corley KC, Boadle-Biber MC. Increase in cortical and midbrain tryptophan hydroxylase activity by intracerebroventricular administration of corticotropin releasing factor: block by adrenalectomy, by RU 38486 and by bilateral lesions to the central nucleus of the amygdala. Neurochem Int 1991;20:81–92.

69. Staner L, Kempenaers C, Simonnet M-P, Fransolet L, Mendlewicz J. 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 1992;86:133–137.

70. Stockmeier CA, Wingenfeld P, Gudelsky GA. Effects of repeated electroconvulsive shock on serotonin 1A receptor binding and receptor mediated hypothermia in the rat. Neuropharmacology 1992; 31:1089–1094.

71. Traskman-Bendz L, Haskett RF, Zis AP. Neuroendocrine effects of L-tryptophan and dexamethasone. Psychopharmacology 1986; 89:85–88.

72. Upadhyaya AK, Pennell I, Cowen PJ, Deakin JF. Blunted growth hormone and prolactin responses to L-tryptophan in depression, a state-dependent abnormality. J Affect Disord 1991;21:213–218.

73. van Praag HM, Lemus C, Kahn R. Hormonal probes of central serotonergic activity: do they really exist? Biol Psychiatry 1987;22: 86–98.

74. Welner SA, de Montigny C, Desroches J, Desjardins P, Suranyi-Cadotte BE. Autoradiographic quantification of serotonin 1A receptors in rat brain following antidepressant drug treatment. Synapse 1989;4:347–352.

75. Young SN, Smith SE, Pihl R, Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 1985;87:173–177.

Back to Chapter